Progress in the development of new vaccines against tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 2, 1997, Pages 95-100

  Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Animal models; BCG; DNA vaccines; Sub unit vaccines; Vaccines

Indexed keywords

BCG VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL; FORECASTING; HUMAN; IMMUNOLOGY; REVIEW; TUBERCULOSIS; VACCINATION;

ANIMALS; BCG VACCINE; FORECASTING; HUMANS; TUBERCULOSIS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0031107541     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rodrigues L, Smith P G. Tuberculosis in developing countries and methods for its control. Trans Royal Soc Trop Med Hyg 1990; 739-744.
2. Huebner R E. Bacillus of Calmette and Guerin (BCG) vaccine. In: Rom WN, Garay S, eds. Tuberculosis p. 893. New York: Little, Brown and Company, 1996.
3. Orme I M. Prospects for new vaccines against tuberculosis. Trends Microbiol 1995; 3: 401-404.
4. Cooper A M, Roberts A D, Rhoades E R, Callahan J M, Getzy D M, Orme I M. The role of IL-12 in acquired immunity to Mycobacterium tuberculosis. Immunology 1995; 84: 423-432.
5. Dannenberg A M. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunology Today 1991; 12: 228-233.
6. Orme I M. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J Immunol 1988; 140: 3589-3593.
7. Donnelly J J, Ulmer J B, Lui M A. Immunization with DNA. J Immunol Methods 1994; 176: 145-152.
8. Silva S L, Lowrie D B. A single mycobacterial protein (hsp60) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. Immunology 1994; 82: 244-248.
9. Wiegeshaus E H, Smith D W. Evaluation of the protective potency of new tuberculosis vaccines. Rev Infect Dis 1989; 11: S484-490.
10. Orme I M, Miller E S, Roberts A D, et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992; 148: 189-196.
11. Silva C L, Silva M F, Pietro R C L R, Lowrie D B. Protection against tuberculosis by passive transfer with T-cell clones recognizing mycobacterial heat-shock protein 65. Immunology 1994; 83: 341-346.
12. van Eden W, Hogervorst E J M, van der Zee R, van Embden J D A, Hensen E J, Cohen I R. The mycobacterial 65kD heat-shock protein and autoimmune arthritis. Rheumatol Int 1989; 9: 187-191.
13. Huygen K, Content J, Denis O, et al. Immunogemcity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine 1996; 8: 893-898.
14. Tascon R E, Colston M J, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nature Medicine 1996; 2: 888-892.
15. Orme I M, Collins F M. Crossprotection against nontuberculous mycobacterial infections by Mycobacterium tuberculosis memory immune T lymphocytes. J Exp Med 1986; 163: 203-208.
16. Orme I M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance, in mice inoculated with nonliving mycobacterial vaccines. Infect Immun 1988; 56: 3310-3312.
17. Andersen P, Askgaard D, Gottschau A, et al. Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand J Immunol 1992; 36: 823-831.
18. Hubbard R D, Flory C M, Collins F M. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 1992; 878: 94-98.
19. Andersen P, Askgaard D, Ljungqvist L, et al. T cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991; 59: 1558-1563.
20. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62: 2536-2544.
21. Roberts A D, Sonnenberg M G, Ordway D J, et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 1995; 85: 502-508.
22. Pal P G, Horwitz M A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992; 60: 4781-4792.
23. Horwitz M A, Lee B E, Dillon B J, et al. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995; 92: 1530-1534.
24. Wiegeshaus E H, McMurray D N, Grover A A, et al. Host-parasite relationships in experimental airborne tuberculosis. III. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis 1970; 102: 422-429.
25. Smith D W, McMurray D N, Wiegeshaus E H, et al. Host-parasite relationships in experimental airborne tuberculosis. IV. Early events in the course of infection in vaccinated and non-vaccinated guinea pigs. Am Rev Respir Dis 1970; 102: 937-949.
26. McMurray D N. Guinea pig model of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control, pp. 113-134. ASM Press 1994.
27. Hanson M S, Bansal G P, Langermann S, et al. Efficacy and safety of live recombinant BCG vaccines. Dev Biol Stand 1995; 84: 229-236.
28. Cirillo J D, Stover C K, Bloom B R, et al. Bacterial vaccine vectors and Bacillus Calmette-Guerin. Clin Infect Dis 1995; 20: 1001-1002.
29. Stover C K, Bansal G P, Hanson M S, et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 1993; 178: 197-209.
30. Abdelhak S, Louzir H, Timm J, et al. Recombinant BCG expressing the leishmania surface antigen Gp63 indices protective immunity against Leishmania major infection in Balb/c mice. Microbiology 1995; 141: 1585-1592.
31. Winter N, Lagrandene M, Gangloff S, et al. Recombinant BCG strains expressing the SIVmac251 nef gene indice proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 1995; 13: 471-478.
32. O'Donnell M A, Aldovini A, Duba R B, et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62: 2508-2514.
33. Murray P J, Aldovini A, Young R A. Manipulation and potentiation of anti-mycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 1996; 93: 934-939.
34. McAdam R A, Weisbrod T R, Martin J, et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect Immun 1995; 63: 1004-1012.
35. Bange F C, Brown A M, Jacobs W R. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect Immun 1996; 64: 1794-1799.
36. Mahairas C G, Sabo P J, Hickey M J, et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-1282.
37. Reyrat J M, Berthet F X, Gicquel B. The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus. Proc Natl Acad Sci USA 1995; 92: 8768-8772.
38. Balasubramanian V, Pavelka M S, Bardarov S S, et al. Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates. J Bacteriol 1996; 178: 273-279.